I was looking at the possible legislation in front of the Philippine government and how much they're budgeting toward COVID-19 response.
https://www.gmanetwork.com/news/news/nation/7...law/story/
The breakdown of the proposed P485-billion appropriation under Bayanihan 3 is as follows:
P55 billion for the procurement of COVID-19 medication and vaccines;
P55 billion for the handling of vaccines, hiring of contact tracers, testing and treatment under PhilHealth, and payment of actual hazard duty pay;
.....
Once enacted into law, the bill shall be effective until the adjournment of session in Congress on June 4, 2021.
P55 billion = $1.15B USD
We already know that the PI is trying to get the Chinese vaccine - that'll cost them some pesos. More pesos for various medications to treat M2M patients...I was figuring they'll have about $250M USD to lay down on leronlimab...until....I ran some numbers....
At "US pricing" ($1500/vial w/4 vials per patient)....$250M would be about 41,000 patients...but their current S/C patient population is about 2,200. If they budgeted for 10,000 patients (40K vials) that would mean about $60M of leronlimab. Let's figure that CytoDyn makes 50% profit (cost of goods, Chiral's cut, and FedEx doesn't work for free) then that's $30M into CytoDyn's checking account. That will just about cover paying off the Streeterville loan ($28M) w/cash.
Long story short...the PI isn't going to clean out the inventory of Leronlimab (1.5M vials). CytoDyn would be lucky to sell 50,000 vials.
CytoDyn isn't going to get rich from sales to the PI.
What's better than revenues is getting real world demonstrated results. Once the world see in plain sight - no secretive double-blinded RCT - then they will line up at NP's Leronlimab stand to get some of the good stuff.
https://www.gmanetwork.com/news/news/nation/7...law/story/
The breakdown of the proposed P485-billion appropriation under Bayanihan 3 is as follows:
P55 billion for the procurement of COVID-19 medication and vaccines;
P55 billion for the handling of vaccines, hiring of contact tracers, testing and treatment under PhilHealth, and payment of actual hazard duty pay;
.....
Once enacted into law, the bill shall be effective until the adjournment of session in Congress on June 4, 2021.
P55 billion = $1.15B USD
We already know that the PI is trying to get the Chinese vaccine - that'll cost them some pesos. More pesos for various medications to treat M2M patients...I was figuring they'll have about $250M USD to lay down on leronlimab...until....I ran some numbers....
At "US pricing" ($1500/vial w/4 vials per patient)....$250M would be about 41,000 patients...but their current S/C patient population is about 2,200. If they budgeted for 10,000 patients (40K vials) that would mean about $60M of leronlimab. Let's figure that CytoDyn makes 50% profit (cost of goods, Chiral's cut, and FedEx doesn't work for free) then that's $30M into CytoDyn's checking account. That will just about cover paying off the Streeterville loan ($28M) w/cash.
Long story short...the PI isn't going to clean out the inventory of Leronlimab (1.5M vials). CytoDyn would be lucky to sell 50,000 vials.
CytoDyn isn't going to get rich from sales to the PI.
What's better than revenues is getting real world demonstrated results. Once the world see in plain sight - no secretive double-blinded RCT - then they will line up at NP's Leronlimab stand to get some of the good stuff.
9
